List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/848292/publications.pdf Version: 2024-02-01



RRUNO MOULIN

#	Article	IF	CITATIONS
1	Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome. New England Journal of Medicine, 2013, 368, 2169-2181.	27.0	1,258
2	Genetics and Outcome of Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 554-562.	4.5	567
3	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney International, 2012, 82, 454-464.	5.2	454
4	Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing. Clinical Pharmacology and Therapeutics, 2010, 87, 721-6.	4.7	280
5	Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study. American Journal of Transplantation, 2009, 9, 1115-1123.	4.7	246
6	Post-Transplant Lymphoproliferative Disorders Occurring After Renal Transplantation in Adults: Report of 230 Cases From the French Registry. American Journal of Transplantation, 2006, 6, 2735-2742.	4.7	237
7	Immunoprophylaxis with Basiliximab Compared with Antithymocyte Globulin in Renal Transplant Patients Receiving MMF-containing Triple Therapy. American Journal of Transplantation, 2002, 2, 48-56.	4.7	226
8	Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome. American Journal of Transplantation, 2013, 13, 663-675.	4.7	224
9	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney International, 2020, 98, 1549-1558.	5.2	213
10	Spectrum of Mutations in Gitelman Syndrome. Journal of the American Society of Nephrology: JASN, 2011, 22, 693-703.	6.1	190
11	Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney International, 1992, 42, 127-135.	5.2	167
12	Epidemiology of Posttransplant Lymphoproliferative Disorders in Adult Kidney and Kidney Pancreas Recipients: Report of the French Registry and Analysis of Subgroups of Lymphomas. American Journal of Transplantation, 2012, 12, 682-693.	4.7	166
13	Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney International, 2021, 99, 1498-1500.	5.2	163
14	Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6â€Month Course of Steroids. American Journal of Transplantation, 2007, 7, 2522-2531.	4.7	160
15	One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation. Transplantation, 2016, 100, 391-399.	1.0	157
16	A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1. Transplantation, 2003, 75, 844-851.	1.0	150
17	European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus, 2009, 18, 257-263.	1.6	131
18	Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney International, 2021, 99, 1487-1489.	5.2	126

#	Article	IF	CITATIONS
19	Post-Transplantation Lymphoproliferative Disorder After Kidney Transplantation: Report of a Nationwide French Registry and the Development of a New Prognostic Score. Journal of Clinical Oncology, 2013, 31, 1302-1309.	1.6	122
20	Persistent Hyperparathyroidism Is a Major Risk Factor for Fractures in the Five Years After Kidney Transplantation. American Journal of Transplantation, 2013, 13, 2653-2663.	4.7	122
21	Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel. Journal of the American College of Cardiology, 2011, 57, 399-408.	2.8	121
22	Cytokine release syndromeâ€associated encephalopathy in patients with COVIDâ€19. European Journal of Neurology, 2021, 28, 248-258.	3.3	114
23	Correction of Postkidney Transplant Anemia Reduces Progression of Allograft Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 360-368.	6.1	110
24	Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clinical Microbiology and Infection, 2014, 20, 109-118.	6.0	105
25	Bardet-Biedl Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 22-29.	4.5	103
26	Risk Factors for BK Virus Infection in the Era of Therapeutic Drug Monitoring. Transplantation, 2013, 95, 1498-1505.	1.0	103
27	Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation, 2003, 76, 930-937.	1.0	99
28	Anti–Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases. Journal of Immunology, 2015, 194, 5129-5138.	0.8	99
29	ATG-Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients. American Journal of Transplantation, 2015, 15, 1028-1038.	4.7	92
30	Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrology Dialysis Transplantation, 2010, 25, 967-976.	0.7	87
31	Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. American Journal of Transplantation, 2017, 17, 1370-1379.	4.7	85
32	Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four-Year Results of the Postconcept Study. American Journal of Transplantation, 2011, 11, 1665-1675.	4.7	84
33	Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrology Dialysis Transplantation, 2006, 21, 1053-1059.	0.7	83
34	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2017, 28, 1603-1613.	6.1	83
35	Incidence of Delayed Graft Function and Wound Healing Complications After Deceased-Donor Kidney Transplantation Is not Affected by De Novo Everolimus. Transplantation, 2009, 88, 69-76.	1.0	75
36	B7–1 Blockade Does Not Improve Post–Transplant Nephrotic Syndrome Caused by Recurrent FSCS. Journal of the American Society of Nephrology: JASN, 2016, 27, 2520-2527.	6.1	75

#	Article	IF	CITATIONS
37	Incidence and Risk Factors of Glucose Metabolism Disorders in Kidney Transplant Recipients: Role of Systematic Screening by Oral Glucose Tolerance Test. Transplantation, 2011, 91, 757-764.	1.0	72
38	An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in deÂnovo kidney transplant patients. Kidney International, 2019, 96, 231-244.	5.2	69
39	Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transplant International, 2010, 23, 1084-1093.	1.6	68
40	Factors Predictive of Medication Nonadherence After Renal Transplantation. Transplantation, 2013, 95, 326-332.	1.0	68
41	In-depth virological assessment of kidney transplant recipients with COVID-19. American Journal of Transplantation, 2020, 20, 3162-3172.	4.7	68
42	Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrology Dialysis Transplantation, 2003, 18, 2147-2153.	0.7	66
43	Neutralizing Antibody–Mediated Response and Risk of BK Virus–Associated Nephropathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 326-334.	6.1	64
44	Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations. American Journal of Transplantation, 2015, 15, 800-805.	4.7	62
45	Fibrosis Progression According to Epithelial-Mesenchymal Transition Profile: A Randomized Trial of Everolimus Versus CsA. American Journal of Transplantation, 2015, 15, 1303-1312.	4.7	61
46	Interstitial Fibrosis Quantification in Renal Transplant Recipients Randomized to Continue Cyclosporine or Convert to Sirolimus. American Journal of Transplantation, 2009, 9, 2552-2560.	4.7	60
47	Impact of Cyclosporine Reduction With MMF: A Randomized Trial in Chronic Allograft Dysfunction. The 'Reference' Study. American Journal of Transplantation, 2006, 6, 2725-2734.	4.7	52
48	Association of Estimated GFR With Platelet Inhibition in Patients Treated With Clopidogrel. American Journal of Kidney Diseases, 2012, 59, 777-785.	1.9	52
49	Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. American Journal of Transplantation, 2016, 16, 2670-2675.	4.7	51
50	Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. British Journal of Haematology, 2006, 134, 602-612.	2.5	50
51	Post-transplant Lymphoproliferative Disorders: Determination of Donor/Recipient Origin in a Large Cohort of Kidney Recipients. American Journal of Transplantation, 2011, 11, 1260-1269.	4.7	48
52	Five-Year Results of a Randomized Trial Comparing De Novo Sirolimus and Cyclosporine in Renal Transplantation: The Spiesser Study. American Journal of Transplantation, 2012, 12, 1801-1810.	4.7	48
53	Bardet–Biedl syndrome highlights the major role of the primary cilium in efficient water reabsorption. Kidney International, 2011, 79, 1013-1025.	5.2	46
54	The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders. Transplantation, 2012, 94, 784-793.	1.0	45

#	Article	IF	CITATIONS
55	Renal Transplantation in Patients with Sarcoidosis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2101-2108.	4.5	43
56	The Spectrum of Kidney Pathology in B-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: A 25-Year Multicenter Experience. PLoS ONE, 2015, 10, e0119156.	2.5	41
57	Torquetenovirus viremia for early prediction of graft rejection after kidney transplantation. Journal of Infection, 2019, 79, 56-60.	3.3	40
58	Preâ€transplant endâ€stage renal diseaseâ€related immune risk profile in kidney transplant recipients predicts postâ€transplant infections. Transplant Infectious Disease, 2016, 18, 415-422.	1.7	39
59	French recommendations for the management of systemic sclerosis. Orphanet Journal of Rare Diseases, 2021, 16, 322.	2.7	37
60	Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options. Nephrology Dialysis Transplantation, 2013, 28, 1994-2002.	0.7	36
61	Advagraf [®] , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. Transplant International, 2016, 29, 860-869.	1.6	34
62	Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant Recipients. Transplantation, 2021, 105, 158-169.	1.0	34
63	Parathyroid Hormone-Related Protein Is a Mitogenic and a Survival Factor of Mesangial Cells from Male Mice: Role of Intracrine and Paracrine Pathways. Endocrinology, 2013, 154, 853-864.	2.8	32
64	Eight-year results of the Spiesser study, a randomized trial comparing <i>de novo</i> sirolimus and cyclosporine in renal transplantation. Transplant International, 2016, 29, 41-50.	1.6	32
65	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
66	A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1663-1670.	4.5	32
67	Pretransplant thymic function predicts acute rejection in antithymocyte globulin–treated renal transplant recipients. Kidney International, 2016, 89, 1136-1143.	5.2	31
68	Renal biopsy practice in France: results of a nationwide study. Nephrology Dialysis Transplantation, 2010, 25, 3579-3585.	0.7	30
69	Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transplant International, 2017, 30, 256-265.	1.6	30
70	Comparing the Bbs10 complete knockout phenotype with a specific renal epithelial knockout one highlights the link between renal defects and systemic inactivation in mice. Cilia, 2015, 4, 10.	1.8	29
71	Recent Changes in Chronic Kidney Disease–Mineral and Bone Disorders and Associated Fractures After Kidney Transplantation. Transplantation, 2017, 101, 1897-1905.	1.0	29
72	Impact of preâ€ŧransplant dialysis modality on postâ€ŧransplant diabetes mellitus after kidney transplantation. Clinical Transplantation, 2011, 25, 794-799.	1.6	28

#	Article	IF	CITATIONS
73	Sequence Variation in Amplification Target Genes and Standards Influences Interlaboratory Comparison of BK Virus DNA Load Measurement. Journal of Clinical Microbiology, 2015, 53, 3842-3852.	3.9	27
74	Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation. Transplant International, 2017, 30, 29-40.	1.6	27
75	Tenofovir-induced acute renal failure in an HIV patient with normal renal function. Nephrology Dialysis Transplantation, 2005, 20, 473-474.	0.7	26
76	Knockdown of parathyroid hormone related protein in smooth muscle cells alters renal hemodynamics but not blood pressure. American Journal of Physiology - Renal Physiology, 2013, 305, F333-F342.	2.7	25
77	Gestational Choriocarcinoma Transmission Following Multiorgan Donation. American Journal of Transplantation, 2010, 10, 2541-2546.	4.7	24
78	End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal Transplantation. Frontiers in Immunology, 2019, 10, 1630.	4.8	24
79	Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients—Results from a proof-of-concept study. American Journal of Transplantation, 2021, 21, 329-337.	4.7	24
80	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney International, 2021, 99, 671-685.	5.2	24
81	Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online. Therapeutic Drug Monitoring, 2018, 40, 285-291.	2.0	23
82	A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2016, 38, 223-229.	2.0	21
83	Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	20
84	Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. Transplant International, 2000, 13, S388-S393.	1.6	19
85	Recurrence of Renal Cell Cancer After Renal Transplantation in a Multicenter French Cohort. Transplantation, 2018, 102, 860-867.	1.0	18
86	Is Sirolimus Responsible for Proteinuria?. Transplantation Proceedings, 2005, 37, 2828-2829.	0.6	17
87	Simultaneous Development of Lymphoma in Recipients of Renal Transplants from a Single Donor: Donor Origin Confirmed by Human Leukocyte Antigen Staining and Microsatellite Analysis. Transplantation, 2005, 79, 79-84.	1.0	16
88	Ruling out nosocomial transmission of Cryptosporidium in a renal transplantation unit: case report. BMC Infectious Diseases, 2016, 16, 363.	2.9	15
89	Localization of Tubular Adaptation to Renal Sodium Loss in Gitelman Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 472-478.	4.5	14
90	Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. American Journal of Transplantation, 2017, 17, 1008-1019.	4.7	13

#	Article	IF	CITATIONS
91	Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: A multicenter retrospective study. Transplant Infectious Disease, 2019, 21, e13058.	1.7	13
92	Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. PLoS ONE, 2019, 14, e0212931.	2.5	13
93	Intraoperative Pleth Variability Index Is Linked to Delayed Graft Function After Kidney Transplantation. Transplantation Proceedings, 2016, 48, 2615-2621.	0.6	11
94	Temporal trends in living kidney donation in France between 2007 and 2017. Nephrology Dialysis Transplantation, 2021, 36, 730-738.	0.7	11
95	Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. Transplant International, 2000, 13, S388-S393.	1.6	10
96	Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: a randomized multicentre trial in kidney transplant recipients. Nephrology Dialysis Transplantation, 2012, 27, 3651-3659.	0.7	10
97	Pregnancy in a Kidney Transplant Woman Under Treatment With Eculizumab forÂAtypical Hemolytic Uremic Syndrome: IsÂlt Safe?. Kidney International Reports, 2019, 4, 733-739.	0.8	10
98	Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study. Clinical Microbiology and Infection, 2021, 27, 1644-1651.	6.0	10
99	Automated office and home phone-transmitted blood pressure recordings in uncontrolled hypertension treated with valsartan and hydrochlorothiazide. Blood Pressure, 2004, 13, 18-24.	1.5	9
100	Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to $30\widehat{a} \in f$ months post-transplant. Clinical Transplantation, 2007, 21, 295-300.	1.6	9
101	Evaluation of Protocol Biopsy Utility 12 Months after Renal Transplantation: A Multicenter Observational Analysis. Journal of Transplantation, 2012, 2012, 1-9.	0.5	8
102	Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Reports in Transplantation, 2017, 2017, 1-6.	0.3	8
103	Tolerability of Enteric-Coated Mycophenolate Sodium to 1 Year in Combination With Cyclosporine and Corticosteroids in Renal Transplant Recipients. Transplantation Proceedings, 2006, 38, 2860-2863.	0.6	7
104	Chronic Lymphocytic Leukemia: A Hazardous Condition Before Kidney Transplantation. American Journal of Transplantation, 2008, 8, 2471-2475.	4.7	7
105	French law: what about a reasoned reimbursement of serum vitamin D assays?. Psychologie & Neuropsychiatrie Du Vieillissement, 2016, 14, 377-382.	0.2	7
106	Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. Molecular Genetics and Metabolism, 2020, 131, 259-266.	1.1	7
107	Néphropathie interstitielle immuno-allergiqueDrug-induced acute interstitial nephritis. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2003, 12, 306-312.	0.1	6
108	Effect of the shipment of cadaveric renal allografts on allograft survival. Nephrology Dialysis Transplantation, 2007, 23, 1054-1060.	0.7	6

#	Article	IF	CITATIONS
109	Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study. Journal of Transplantation, 2014, 2014, 1-8.	0.5	6
110	Immune reconstitution with two different rabbit polyclonal anti-thymocytes globulins. Transplant Immunology, 2017, 45, 48-52.	1.2	6
111	Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort. Transplantation, 2020, 104, 2148-2157.	1.0	6
112	Granulomatous Inflammation and Hypercalcemia in Patients With Severe Systemic Oxalosis. Kidney International Reports, 2022, 7, 343-349.	0.8	6
113	Living kidney donor evaluation for all candidates with normal estimated GFR for age. Transplant International, 2021, 34, 1123-1133.	1.6	3
114	Atrial natriuretic peptide in the renal response to an acute protein load. International Journal of Clinical Pharmacology Research, 1990, 10, 211-6.	0.4	3
115	A gain-of-function variant in the Wiskott-Aldrich syndrome gene is associated with a MYH9-related disease-like syndrome. Blood Advances, 2022, 6, 5279-5284.	5.2	2
116	Giant colonic ulcer and pseudopolyps in an immunodepressed patient. Endoscopy, 2011, 43, 926-927.	1.8	1
117	Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study. BMC Nephrology, 2016, 17, 58.	1.8	1
118	How can a vascular surgeon help in kidney transplantation. Journal of Cardiovascular Surgery, 2017, 58, 351-359.	0.6	1
119	The Authors Reply. Kidney International Reports, 2019, 4, 1658-1659.	0.8	1
120	Transplant center characteristics associated with livingâ€donor kidney transplantation: a cohort study with a hierarchical modeling approach. Transplant International, 2019, 32, 865-875.	1.6	1
121	Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report. BMC Nephrology, 2020, 21, 405.	1.8	1
122	Hemodynamic Management During Kidney Transplantation: A French Survey. Transplantation Proceedings, 2021, 53, 1450-1453.	0.6	1
123	Highâ€flow arteriovenous fistula and hemodynamic consequences at 1 year after kidney transplantation. Seminars in Dialysis, 2021, , .	1.3	0
124	Response to a Letter to the Editor regarding "Granulomatous inflammation and hypercalcemia in patients with severe systemic oxalosisâ€, by Perrin et al., KI Reports 2021. Kidney International Reports, 2022, 7, 931.	0.8	0